Bright Minds Biosciences Inc. (DRUG) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2024, filed Dec 31, 2024. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the DRUG SEC filings page.
This page shows Bright Minds Biosciences Inc. (DRUG) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Bright Minds Biosciences Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Bright Minds Biosciences Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Bright Minds Biosciences Inc. reported a net loss of $2.1M while operations used $1.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Bright Minds Biosciences Inc. reported a net loss of $2.1M in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
Bright Minds Biosciences Inc. earned -$0.48 per diluted share (EPS) in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Bright Minds Biosciences Inc. held $4.2M in cash as of fiscal year 2024; no long-term debt figure is on record for that period.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
Bright Minds Biosciences Inc.'s ROE was -50.6% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 61.1 percentage points from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Capital Allocation
Bright Minds Biosciences Inc. invested $873K in research and development in fiscal year 2024. This represents a decrease of 76.4% from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
DRUG Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K |
|---|---|---|---|---|---|
| R&D Expenses | $873K-76.4% | $3.7M-58.3% | $8.9M+77.8% | $5.0M+1770.6% | $266K |
| Interest Expense | $7K-54.6% | $15K+823.5% | $2Kn/m | $0n/m | $0 |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Net Income | -$2.1Mn/m | -$5.4Mn/m | -$10.9Mn/m | -$6.8Mn/m | -$361K |
| EPS (Basic) | -$0.48n/m | -$1.46 | -$4.41n/m | -$3.80 | N/A |
| EPS (Diluted) | -$0.48n/m | -$1.46 | -$4.41n/m | -$3.80 | -$0.10 |
| Diluted Shares (Avg) | 4M+15.9% | 4M | 2M+37.6% | 2M | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, SG&A Expenses, Operating Income, EBITDA.
DRUG Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K |
|---|---|---|---|---|---|
| Total Assets | $4.5M-11.1% | $5.1M-42.2% | $8.8M-44.4% | $15.8M+2293.5% | $661K |
| Current Assets | $4.4M-12.0% | $5.0M-42.1% | $8.7M-45.1% | $15.8M+2298.7% | $659K |
| Cash & Equivalents | $4.2M-15.1% | $5.0M-41.0% | $8.5M-45.8% | $15.6M+2496.9% | $600K |
| Goodwill | N/A | N/A | $0-100.0% | $2K+5.1% | $2K |
| Total Liabilities | $421K+102.7% | $208K-81.5% | $1.1M+122.9% | $504K+344.8% | $113K |
| Current Liabilities | $391K+88.6% | $208K-80.6% | $1.1M+112.5% | $504K | N/A |
| Non-Current Liabilities | $29Kn/m | $0-100.0% | $52Kn/m | $0 | N/A |
| Total Equity | $4.1M-15.9% | $4.9M-36.4% | $7.7M-49.9% | $15.3M+2696.8% | $547K |
| Retained Earnings | -$25.4Mn/m | -$23.3Mn/m | -$17.6Mn/m | -$7.3Mn/m | -$420K |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Long-Term Debt.
DRUG Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
DRUG Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K |
|---|---|---|---|---|---|
| Return on Equity | -50.6%+61.1pp | -111.7%+30.2pp | -141.9%-97.4pp | -44.6%+21.3pp | -65.9% |
| Return on Assets | -45.9%+61.3pp | -107.2%+16.6pp | -123.8%-80.6pp | -43.2%+11.4pp | -54.6% |
| Current Ratio | 11.32-12.9x | 24.26+16.1x | 8.11-23.3x | 31.38 | N/A |
| Liabilities-to-Equity | 0.10+0.1x | 0.04-0.1x | 0.15+0.1x | 0.03-0.2x | 0.21 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Bright Minds Biosciences Inc. DRUG | FY2024 | N/A | -$2.1M | N/A | $517.7M | — |
| Larimar Therapeutics, Inc. LRMR | FY2025 | N/A | -$165.7M | N/A | $244.1M | — |
| Tectonic Therapeutic, Inc. TECX | FY2025 | N/A | -$74.2M | N/A | $392.4M | — |
| Assembly Biosciences, Inc ASMB | FY2025 | $72.3M | -$6.1M | -8.5% | $404.0M | 73/100 |
| Immuneering Corporation IMRX | FY2025 | N/A | -$56.0M | N/A | $241.3M | — |
| MBX Biosciences, Inc. MBX | FY2025 | N/A | -$87.0M | N/A | $2.3B | — |
Where Bright Minds Biosciences Inc. Ranks
Frequently Asked Questions
Is Bright Minds Biosciences Inc. profitable?
No, Bright Minds Biosciences Inc. (DRUG) reported a net loss of $2.1M in fiscal year 2024.
What is Bright Minds Biosciences Inc.'s return on equity (ROE)?
Bright Minds Biosciences Inc. (DRUG) has a return on equity of -50.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Bright Minds Biosciences Inc.'s operating cash flow?
Bright Minds Biosciences Inc. (DRUG) recorded an outflow of $1.4M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Bright Minds Biosciences Inc.'s total assets?
Bright Minds Biosciences Inc. (DRUG) had $4.5M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Bright Minds Biosciences Inc. spend on research and development?
Bright Minds Biosciences Inc. (DRUG) invested $873K in research and development during fiscal year 2024.
What is Bright Minds Biosciences Inc.'s current ratio?
Bright Minds Biosciences Inc. (DRUG) had a current ratio of 11.32 as of fiscal year 2024, which is generally considered healthy.
What is Bright Minds Biosciences Inc.'s liabilities-to-equity ratio?
Bright Minds Biosciences Inc. (DRUG) had a liabilities-to-equity ratio of 0.10 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2024, because the filing data we hold for that year carries no long-term debt figure.
What is Bright Minds Biosciences Inc.'s return on assets (ROA)?
Bright Minds Biosciences Inc. (DRUG) had a return on assets of -45.9% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Bright Minds Biosciences Inc.'s P/E ratio?
Bright Minds Biosciences Inc. (DRUG) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $517.7M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bright Minds Biosciences Inc.'s price-to-sales ratio?
Bright Minds Biosciences Inc. (DRUG) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $517.7M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Bright Minds Biosciences Inc.'s Piotroski F-Score?
Bright Minds Biosciences Inc. (DRUG) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Bright Minds Biosciences Inc.'s earnings high quality?
Bright Minds Biosciences Inc. (DRUG) reported a net loss of $2.1M while operations used $1.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.